Qualia NAD+(R) Increases NAD+ In Human Participants: A Randomized, Double-Blind, Placebo-Controlled Study
Blomquist, S. A.; Kelly, G.; Adaes, S.; Ardagh, A.; Ramer, S.; Scuba, W.
Show abstract
BackgroundNicotinamide adenine dinucleotide (NAD) is a crucial coenzyme involved in cellular energy homeostasis whose levels decline notably with aging, which has prompted interest in NAD+ boosting to help combat age-related diseases and dysfunction. Numerous clinical trials have demonstrated safety and efficacy for B3 vitamins, such as nicotinamide riboside (NR), to increase NAD+ levels and augment the NAD+ metabolome. Limited impact on clinically relevant outcomes or quality of life have been demonstrated, however. ObjectiveThis randomized, double-blind, placebo-controlled, remote pilot study examined the effects of supplementation with Qualia NAD+(R) on whole blood NAD+ levels and quality of life measures. MethodsStudy participants consumed Qualia NAD+ daily for 28 consecutive days. NAD+ levels were the primary outcome and measured using a self-administered, non-invasive blood spot assay test conducted at baseline and at study end. Quality of life questionnaires were the secondary outcomes and reported bi-weekly. NAD+ levels and questionnaire data were analyzed using a linear mixed-effects model to compare within-group and between-group differences over time as compared to baseline. Independent t-tests were utilized to compare safety and tolerability between study groups. ResultsTwenty-five healthy adults aged 40 - 65 (56% female) consumed Qualia NAD+ (n = 9) or placebo (n = 16) Overall, Qualia NAD+ significantly increased NAD+ levels an average of 74% compared to a 4% increase observed in the placebo group (p < 0.001). Within-groups comparisons for Qualia NAD+, and changes in NAD+ levels comparing Qualia NAD+ and placebo were also significant (p < 0.001). Improvements in the overall and somatic categories (p = 0.02 and p = 0.04) were observed for males only comparing baseline to the end of the study. No adverse events were reported. ConclusionsQualia NAD+, a novel nutraceutical formulated with multiple vitamins, nutrients, and botanical compounds, effectively increased whole blood NAD+ levels and may improve some symptoms of aging in males. Clinicaltrials.gov identifier: NCT06812416.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: the CLINMIR Pilot Study 94%
- Use of Metabolomic Profiling to Understand Variability in Adiposity Changes Following an Intentional Weight Loss Intervention in Older Adults 94%
- Oral bioavailability and metabolism of hydroxytyrosol from food supplements 93%
Similar papers in this journal
- Effects of Minimally Processed Red Meat Within a Plant-Forward Diet on Biomarkers of Physical and Cognitive Aging: A Randomized Controlled Crossover Feeding Trial 95%
- The effect of exogenous ketones on signs and symptoms of schizophrenia spectrum and bipolar disorders: study protocol for a triple-blind, randomized, controlled cross-over pilot study 93%
- Weight loss with different types of fasting in patients with type two diabetes and hypertension: a randomized clinical trial 92%
Similar papers in this journal
- Dietary Fatty Acids and Epigenetic Aging in US Adults: Results from the National Health and Nutrition Examination Survey 93%
- Mitorubin, berberrubine-based compounds that improve mitochondrial function, exhibit cardioprotective effects against age-related cardiac dysfunction 92%
- Reporting quality, effect sizes, and biases for aging interventions: a methodological appraisal of the DrugAge database 91%
Similar papers in this journal
- In Vivo Mitochondrial ATP Production Is Improved in Older Adult Skeletal Muscle After a Single Dose of Elamipretide in a Randomized Trial 94%
- The impact of outdoor walking interventions on frailty among older adults with mobility limitations: findings from the Getting Older Adults Outdoors (GO-OUT) study 93%
- Menopausal symptom burden as a predictor of mid- to late-life cognitive function and mild behavioral impairment symptoms: A CAN-PROTECT study 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.